top of page

what is Multiple myeloma?

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bones.


Multiple myeloma is a form of cancer that occurs due to abnormal and uncontrolled growth of plasma cells in the bone marrow.

latest program

pavlos_msaouel.jpg.resize.405.575_edited

How Can Myeloma Patients Facing Disparities Be More Proactive in Their Care?

Dr. Victoria Vardell of the Huntsman Cancer Institute of Utah discusses her study where key findings reveal Black patients are less likely to receive a stem cell transplant (SCT) and encourages patients to ask questions of their providers until they have a complete understanding.

What is Multiple Myeloma?

Programs

January 13, 2020

Screen Shot 2019-12-15 at 10_edited.jpg

How Can Myeloma Patients Facing Disparities Be More Proactive in Their Care?

Dr. Victoria Vardell of the Huntsman Cancer Institute of Utah discusses her study where key findings reveal Black patients are less likely to receive a stem cell transplant (SCT) and encourages patients to ask questions of their providers until they have a complete understanding.

December 18, 2019

Screen Shot 2019-12-15 at 10_edited.jpg

2020 Shaping Up To Be Big Year for Multiple Myeloma Treatment

Dr. Sikander Ailawadhi of Mayo Clinic provides high-level highlights for multiple myeloma from the 61st American Society of Hematology (ASH) Meeting in Orlando, Florida.

January 13, 2020

Screen Shot 2019-12-15 at 10_edited.jpg

Does Treatment Adherence in Myeloma Impact Outcomes?

Myeloma expert Dr. Sikander Ailawadhi of Mayo Clinic breaks down the importance of treatment adherence and disease management in multiple myeloma in order to get the maximum benefit. In Dr. Ailawadhi's own words: "In myeloma it has been shown again and again, if you use the right treatment for the right duration and you get a deep response, you are more likely to do better."

December 18, 2019

Screen Shot 2019-12-15 at 10_edited.jpg

ASH 2019: Good News for Myeloma Treatment Today, Still Addressing Race-Associated Risks

Respected myeloma expert, Dr. Ajay Kumar Nooka, provides an update from the 61st American Society of Hematology (ASH) meeting. Dr. Nooka shares why this is a good time in myeloma research and the important work that remains around myeloma treatment disparities for people of color.

December 19, 2019

Screen Shot 2019-12-15 at 10_edited.jpg

ASH 2019: Disparities Around Accessing Health Technology Revealed for a Subset of Myeloma Patients

Is the cost of care in treating multiple myeloma higher for certain populations? In this Diverse Health Hub interview, Dr. Sikander Ailawadhi of Mayo Clinic, discusses disparities around access to care in multiple myeloma from the 61st American Society of Hematology (ASH) Meeting in Orlando, Florida.

Programs

Clinical trials

More information coming soon.

Clinical Trials

Noted disparities

More information coming soon.

Noted Disparities

News

More information coming soon.

News
bottom of page